Tao Synergies (TAOX) closed at $2.54 on November 6, 2026, up 8.3% from the previous close, on volume of 71,356 shares (30-day average 143,451).
Data as of November 6, 2026.
No press releases found.
Market Chameleon (Mon, 20-Oct 7:08 AM ET)
$11 Million Private Placement Reflects Confidence in TAOX's DeAI Strategy
Market Chameleon (Tue, 14-Oct 5:42 AM ET)
TAO Synergies Inc is mainly focused on developing a product platform based on its drug candidate, Bryostatin-1, for the treatment of Alzheimer's disease. The company is also evaluating Bryostatin-1 for other neurodegenerative and cognitive conditions, including Fragile X syndrome and Multiple Sclerosis, which have progressed through pre-clinical testing.
Tao Synergies trades on the NASDAQ stock market under the symbol TAOX.
As of November 6, 2026, TAOX stock price climbed to $2.54 with 71,356 million shares trading.
TAOX has a beta of 1.02, meaning it tends to be more sensitive to market movements. TAOX has a correlation of 0.02 to the broad based SPY ETF.
TAOX has a market cap of $20.43 million. This is considered a Sub-Micro Cap stock.
The top ETF exchange traded funds that TAOX belongs to (by Net Assets): VXF, VTI, IWC, DFMC.
TAOX has underperformed the market in the last year with a price return of -68.3% while the SPY ETF gained +10.8%. TAOX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -26.2% and -23.3%, respectively, while the SPY returned -4.1% and -3.2%, respectively.
TAOX support price is $2.19 and resistance is $2.50 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TAOX shares will trade within this expected range on the day.
